In a report published by Morgan Stanley, IHS IHS organic revenue growth hit 9 percent.
Morgan Stanley said that IHS delivered a solid quarter, driven by stronger-than-expected organic growth of 9%, up from 6% in Q4, a good recovery after last quarter's stagnation in organic growth. “The organic growth rate inherent in the deferred revenue was 14%, up from 10% in the previous two quarters, which bodes well for future results. While margins were lower than we anticipated, management reiterated confidence in the goal of 35% by 2013. Though we believe the company has significant growth and margin expansion potential, we remain Equal-weight on the stock as it is trades at the highest multiple in its peer group (on a standardized basis) at 18.1x our CY11E EBITDA vs. the peer average of 13.7x.”
IHS closed yesterday at $85.79.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.